New hope for kids with rare, deadly lung disease
NCT ID NCT05167825
Summary
This study tested a drug called macitentan in Japanese children with pulmonary arterial hypertension (PAH), a serious condition where high blood pressure damages the lungs and heart. The main goal was to see if taking the drug for 24 weeks improved how well the heart and lungs worked. It also looked at the drug's safety, how it moved through the body, and its effects on children's ability to be active and their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fukuoka Children's Hospital
Fukuoka, 813-0017, Japan
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
Institute of Science Tokyo Hospital
Bunkyō City, 113 8519, Japan
-
Nagano Children's Hospital
Azumino-shi, 399-8288, Japan
-
National Center for Child Health and Development
Setagaya Ku, 157 8535, Japan
-
National Cerebral and Cardiovascular Center
Suita-Shi, 564-8565, Japan
-
Okayama University Hospital
Okayama, 700 8558, Japan
-
Osaka University Hospital
Suita-shi, 565-0871, Japan
-
The University of Tokyo Hospital
Tokyo, 113-8655, Japan
-
Toho University Medical Center Omori Hospital
Ōta-ku, 143-8541, Japan
-
Tokyo Women's Medical University Hospital
Shinjuku-ku, 162-8666, Japan
Conditions
Explore the condition pages connected to this study.